Drugs & Targets Sarclisa in combination with carfilzomib, dexamethasone receives FDA approval for relapsed or refractory multiple myeloma April 02, 2021Vol.47 No.13
Drugs & Targets Futibatinib receives Breakthrough Designation from FDA for advanced cholangiocarcinoma April 02, 2021Vol.47 No.13
Drugs & Targets FDA issues Complete Response Letter on Keytruda in TNBC indication April 02, 2021Vol.47 No.13
Drugs & Targets Huyabio International and BMS to collaborate on melanoma clinical April 02, 2021Vol.47 No.13
Drugs & Targets European Commission approves Cabometyx + Opdivo for first-line advanced renal cell carcinoma April 02, 2021Vol.47 No.13
Drugs & Targets Copiktra receives Positive CHMP Opinion for relapsed and refractory CLL and refractory FL April 02, 2021Vol.47 No.13
Conversation with The Cancer Letter Targeted therapies and better outcomes for small cell lung cancer? NCI study on actionable germline mutations finds a link March 26, 2021Vol.47 No.12By Matthew Bin Han Ong
